Evidence Hub

A Comparative Randomized Clinical Study on Covid-19 Positive Hospitalized Patients Supplemented With NASAFYTOL

ClinicalTrials.gov · COMPLETED, 2022

51 participants

Abstract

The objective of this study is to evaluate the effect and safety of NASAFYTOL® on COVID-19 positive hospitalized patients as a supportive supplementation to standard-of-care in improving clinical parameters safely during hospital admission (maximum 14 days).

The study is a standard-of-care comparative, open, parallel two-arms and randomized trial in 50 adult patients positive to COVID-19 infection and hospitalized. It will be monocentric but may be extended to several investigation sites (multicentric) depending on the evolution of the epidemic within the hospitals.

Conditions: Coronavirus Infection.

Primary outcome: Improvement of the patient's clinical condition based on the WHO ordinal outcomes score; Improvement of the patient's clinical condition based on the WHO ordinal outcomes score; Duration of hospitalization; In-hospital mortality; Temperature (fever); Temperature (fever); Need of oxygen therapy; Tolerance as defined by the Incidence of Adverse Events (AE); Tolerance as defined by the incident of Serious Adverse Events (SAE); Compliance using the pill count; Blood test; Blood test; Blood test.

Enrollment: 51 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 51 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free